Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab Combined With Chemotherapy in Bone Metastases of Unknown Primary
NCT05241132Phase 2Unknown
- Start
- Nov 2021
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in cancer of unknown primary (CUP). Primary endpoint: Objective Response Rate at 3 years. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
cancer of unknown primary (CUP)
Beyond the preview
Go deeper on NCT05241132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05241132.